Christopher Viehbacher - Dec 1, 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
President and CEO, Director
Signature
/s/ Wendell Taylor, attorney-in-fact for Christopher A. Viehbacher
Stock symbol
BIIB
Transactions as of
Dec 1, 2022
Transactions value $
$0
Form type
4
Date filed
12/5/2022, 04:11 PM
Previous filing
Nov 21, 2022
Next filing
Feb 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Stock Option Award $0 +80.5K $0.00 80.5K Dec 1, 2022 Common Stock 80.5K $301.85 Direct F1
transaction BIIB Restricted Stock Unit Award $0 +7.04K $0.00 7.04K Dec 1, 2022 Common Stock 7.04K Direct F2, F3
transaction BIIB Performance Stock Unit Award $0 +46K $0.00 46K Dec 1, 2022 Common Stock 46K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Options are eligible to vest and become exercisable in approximately equal annual installments on the first, second and third anniversaries of the grant date of December 1, 2022.
F2 Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.
F3 Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022.
F4 This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.